Chromosomal and genetic alterations of 7,12-dimethylbenz[a]anthracene- induced melanoma from TP-ras transgenic mice

Molecular Carcinogenesis

Volumn 20, Issue 1, 1997, Pages 78-87

  Gause, Paul R ^a   Lluria Prevatt, Maria ^a   Keith, W Nicol ^b   Balmain, Allan ^b   Linardopolous, Spiros ^b   Warneke, James ^a   Powell, Marianne B ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Fluorescence in situ hybridization; Melanoma; p16; Transgenic mice

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; DNA; PROTEIN P16;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CHROMOSOME 11; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 4; CHROMOSOME 6; CHROMOSOME ABERRATION; CHROMOSOME PAINTING; CONFERENCE PAPER; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; MELANOMA; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; SKIN CARCINOGENESIS; SOUTHERN BLOTTING; TRANSGENIC MOUSE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CARCINOGENS; CARRIER PROTEINS; CHROMOSOME ABERRATIONS; CHROMOSOMES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; GENES, RAS; IN SITU HYBRIDIZATION, FLUORESCENCE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; MICE, TRANSGENIC;

ANIMALIA; MUS MUSCULUS;

EID: 0030809159     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199709)20:1<78::AID-MC9>3.0.CO;2-E     Document Type: Conference Paper

References (42)

1. Thompson FH, Emerson J, Olson S, et al. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 83:93-104, 1995.
2. Cowan JM, Halaban R, Frankke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Nat Cancer Inst 80:1159-1164, 1988.
3. Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions of human chromosome 9p21 in melanoma. Proc Natl Acad Sci USA 89:10557-10561, 1992.
4. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993.
5. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in the genesis of many tumor types. Science 264:436-440, 1994.
6. Glendening JM, Flores JF, Walker GJ, Stone S, Albino AP, Fountain JW. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res 55:5531-5535, 1995.
7. Nagase H, Bryson S, Cordell H, Kemp CJ, Fee F, Balmain A. Distinct genetic loci control development of benign and malignant skin tumours in mice. Nat Genet 10:424-429, 1995.
8. Kemp CJ, Fee F, Balmain A. Allelotype analysis of mouse skin tumors using polymorphic microsatellites: Sequential genetic alterations on chromosomes 6, 7 and 11. Cancer Res 53:6022-6027, 1993.
9. Burns PA, Bremner R, Balmain A. Genetic changes during mouse skin tumorigenesis. Environ Health Perspect 93:41-44, 1991.
10. Bremner R, Kemp CJ, Balmam A. Induction of different genetic changes by different classes of chemical carcinogens during progression of mouse skin tumors. Mol Carcinog 11:90-97, 1994.
11. Brown K, Buchmann A, Balmain A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Nat Acad Sci USA 87:538-542, 1990.
12. Bremner R, Balmain A. Genetic changes in skin tumor progression: Correlation between presence of mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 61:407-417, 1990.
13. Mintz B, Silvers WK. Transgenic mouse model of malignant skin melanoma. Proc Natl Acad Sci USA 90:8817-8821, 1993.
14. Romerdahl CA, Stephens LC, Bucana C, Kripke ML. The role of ultraviolet radiation in the induction of melanocytic skin tumors in inbred mice. Cancer Communications 1:209-216, 1989.
15. Berkelhammer J, Oxendandler RW, Hook RR, Hennessy JJ. Development of a new melanoma model in C57B1/6 mice. Cancer Res 42:3157-3163, 1982.
16. Powell MB, Hyman P, Bell OD, Balmain A, Brown K, Alberts D, Bowden GT. Hyperpigmentation and melanocytic hyperplasia in transgenic mice expressing the human T24 Ha-ras gene regulated by a mouse tyrosinase promoter. Mol Carcinog 12:82-90, 1995.
17. Carter NP. Cytogenetic analysis by chromosome painting. Cytometry 18:2-10, 1994.
18. Rabbitts P, Impey H, Heppell-Parton A, et al. Chromosome specific paints from a high resolution flow karyotype of the mouse. Nat Genet 9:369-375, 1995.
19. Telenius H, et al. Degenerate oligonucleotide-primed PCR: General amplification of target DNA by a single degenerate primer. Genomics 13:718-725, 1992.
20. Bailleul B, Lang J, Wilkie N, Balmain A. A human T24 Ha-ras cassette suitable for expression studies in eukaryotic cells. Nucleic Acids Res 16:359, 1988.
21. Yamamoto H, Takeuchi S, Toshiyuki K, Sato C, Takeuchi T. Melanin production in cultured albino melanocytes transfected with mouse tyrosinase cDNA. Jpn J Genet 64:121-135, 1989.
22. Bennett DC, Copper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 39:414-418, 1987.
23. Meltzer P, Leibovitz A, Dalton W, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br J Cancer 63:727-735, 1991.
24. Murphy DS, Hoare SF, Going JJ, et al. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis. J Nat Cancer Inst 87:1694-1704, 1995.
25. Meltzer P, Leibovitz A, Dalton W, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br J Cancer 63:727-735, 1991.
26. Withoff S, Keith WN, Knol AJ, et al. Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer 74:502-507, 1996.
27. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual, Second ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989.
28. INK4b in undifferentiated mouse skin tumors. Cancer Res 55:5168-5172, 1995.
29. Davis LM, Caspary WJ, Sakallah SA, et al. Loss of heterozygosity in spontaneous and chemically induced tumors of the B6C3F1 mouse. Carcinogenesis 15:1637-1645, 1994.
30. INK48 genes. Oncogene 11:635-645, 1995.
31. Dietrich WF, Radany EH, Smith JS, Bishop JM, Hanahan D, Lander ES. Genome-side search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16. Proc Natl Acad Sci USA 91:9451-9455, 1994.
32. Fountain JW, Bale SJ, Jousman DE, Dracopoli NC. Genetics of melanoma. Cancer Surv 9:645-671, 1990.
33. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the 9p melanoma susceptibility locus. Nat Genet 8:22-26, 1994.
34. Parmiter AH, Balban G, Clark WH Jr, Nowell PC. Possible involvement of the chromosome region 10q24-26 in early stages of melanocytic neoplasia. Cancer Genet Cytogenet 30:313-317, 1988.
35. Nobori T, Muira K, Wu D, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994.
36. Lui Q, Neuhausen S, McClure M, et al. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene 10:1061-1067, 1995.
37. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 8:15-21, 1994.
38. Gruis NA, van der Velden PA, Sandkuijl LA, et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 10:351-353, 1995.
39. INK4A mutation and protein dysfunction in a family with inherited melanoma. Oncogene 11:405-412, 1995.
40. Ohta M, Nagai H, Shimizu M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 54:5269-5272, 1994.
41. Puig S, Ruiz A, Lazaro C, et al. Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside of the p16 (CDKN2) gene. Am J Hum Genet 57:395-402, 1995.
42. Reed JA, Loganzo F Jr, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res 55:2713-2718, 1995.